Paion Value Stock - Dividend - Research Selection
Market price: 1,80 EUR
Paion Fundamental data and company key figures of the share
|Annual reports in EUR|
|Net operating cash flow||-2.846.930|
|Free cash flow||-2.862.190|
|Liabilities & Shareholders equity||24.911.800|
|Diluted shares outstanding||63.918.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||139.542.032,00 USD|
|Raw Data Source||IFRS in Millionen EUR|
|Stock Split||2021-03-24,971.000000/954.000000; 2017-02-10,612.000000/607.000000; 2014-06-20,599.000000/538.000000; 2013-12-23,818.000000/795.000000|
Description of the company
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for out-patient and hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in final stage of clinical development for use in procedural sedation, as well as in other indications, such as general anesthesia and intensive care unit sedation. It has partnerships and license agreements with Cosmo Pharmaceuticals, Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm, Pharmascience, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.